Preview: UroGen Pharma's Earnings
Portfolio Pulse from Benzinga Insights
UroGen Pharma (NASDAQ:URGN) is expected to release its quarterly earnings report on Tuesday, 2023-11-14, with an estimated EPS of $-0.85. Investors are looking for a beat on this estimate and positive guidance for future growth. Historically, URGN's stock price has been sensitive to earnings performance and guidance. Last quarter, URGN beat the EPS estimate by $0.11, leading to a 4.48% stock price increase the following day. Over the last year, URGN shares have risen by 25.99%, indicating a bullish sentiment among long-term shareholders.
November 13, 2023 | 3:01 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
UroGen Pharma is anticipated to report its quarterly earnings with an estimated EPS of $-0.85. A beat on this estimate and positive future guidance could positively impact the stock price, as seen in the last quarter with a 4.48% rise post-earnings. Long-term shareholders are bullish, reflected in the 25.99% stock increase over the past 52 weeks.
Given URGN's history of stock price sensitivity to earnings performance and guidance, a positive report could lead to a short-term price increase. The previous quarter's beat and subsequent stock rise, along with the overall bullish trend over the past year, support this potential outcome. However, the market's reaction can be unpredictable, and external factors could influence the stock's movement.
CONFIDENCE 80
IMPORTANCE 90
RELEVANCE 100